Octreotide is a cyclic eight-amino-acid somatostatin analog that binds preferentially to SST2 and SST5 receptors, suppressing growth hormone, IGF-1, and gut hormone secretion. It is the long-standing standard of care for acromegaly and for the symptomatic control of neuroendocrine tumors (NETs) and carcinoid syndrome, marketed in the US for decades as Sandostatin (immediate-release) and Sandostatin LAR (monthly intramuscular depot) and as the oral capsule Mycapssa from Chiasma/Amryt.
The modality is now under active reformulation pressure. Camurus's Oclaiz (CAM2029), a once-monthly subcutaneous depot built on the company's FluidCrystal lipid technology, posted roughly five-fold higher bioavailability versus traditional IM octreotide across the two Phase 3 ACROINNOVA trials and received EU and UK marketing authorizations in 2025. The US NDA has now drawn two Complete Response Letters tied to a single third-party manufacturer's September 2024 cGMP inspection; resubmission is expected Q4 2026.
Stories here cover octreotide reformulations, the Oclaiz US regulatory track, and the broader somatostatin-analog competitive set. See [[oclaiz]], [[camurus]], and [[acromegaly]] for adjacent threads.
Camurus said on June 10 that the FDA had issued a Complete Response Letter on the Oclaiz (CAM2029) NDA, the second the program has received and the second based solely on unresolved observations from a September 2024 cGMP inspection at a third-party contract manufacturer. The CRL did not cite clinical efficacy or safety. Camurus expects to resubmit in Q4 2026 with a second validated manufacturer; an approval pushed to the first half of 2027 leaves the US launch about a year behind the EU and UK rollouts (under the Oczyesa brand) that landed in 2025.
Camurus's PDUFA target action date for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on FluidCrystal technology, was June 10, and as of June 11 neither the FDA nor Camurus has announced an approval. The acromegaly decision sits in the unannounced-pending bucket that sometimes precedes a same-week communication. Camurus has previously said its US commercial team is launch-ready, with about 20 sales reps active and a Q3 2026 launch targeted if approved; EU and UK marketing authorizations landed in 2025.
Camurus's resubmitted NDA for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target action date of June 10. The resubmission, accepted in January 2026 after a Complete Response Letter tied solely to a third-party manufacturing inspection, rests on data from seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would put Oclaiz alongside Crinetics' Palsonify (paltusotine) as the second new-mechanism acromegaly therapy in the past year, with the Camurus FluidCrystal differentiation focused on a small-volume monthly self-injection.
Camurus' Oclaiz (CAM2029), a once-monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target date of June 10 for acromegaly. The resubmitted NDA, accepted after a Complete Response Letter tied to a third-party manufacturing inspection, rests on seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would add a peptide depot to the somatostatin-analog market alongside Crinetics' newly launched oral Palsonify.
Camurus's Oclaiz (CAM2029) — a once-monthly subcutaneous octreotide FluidCrystal depot delivered via prefilled autoinjector — has an FDA Prescription Drug User Fee Act target action date of June 10, 2026, following an October 2024 Complete Response Letter tied to a third-party manufacturer's cGMP inspection. CAM2029's ACROINNOVA Phase 3 program documented approximately five-fold higher bioavailability versus the currently approved long-acting intramuscular octreotide formulation. The June PDUFA sets up a back-to-back acromegaly decision pair with Crinetics' Palsonify (paltusotine), already approved in the EU on April 27 and reported $10.3M in Q1 US net product revenue (covered above). Both target the same patient population through different routes — once-daily oral nonpeptide vs once-monthly subcutaneous peptide depot.